Ionis Pharmaceuticals, Inc. - Common Stock (IONS)

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam Therapeutics.

Ionis (IONS) Q3 2025 Earnings Call Transcript

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth.

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of

The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.

Ionis reports positive pivotal study results for zilganersen in Alexander disease, showing gait speed benefits and strong safety data.

FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months.

Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events.